Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

Figure 1

Upregulation of Mcl-1 is correlated with ABT-263 resistance in HCC cells. (A) The expression profiles of Bcl-2, Bcl-xL and Mcl-1 were analyzed by Western blot in four HCC cell lines, taking α-tubulin as a loading control. (B) HCC cells were treated with 5 μM ABT-263 for 18 h, then the expression levels of Mcl-1, Bcl-2 and Bcl-xL were analyzed by Western blot. (C) Hep3B and Huh7 cells were transfected with either Bcl-2 siRNA (or control siRNA) or pcDNA3-Bcl-2 plasmid (or control plasmid pcDNA3.0) for 36 h, then the level of Mcl-1 was analyzed by Western blot. (D) Hep3B and Huh7 cells were transfected with control siRNA or Mcl-1 siRNA for 36 h, then Mcl-1 protein level was analyzed by Western blot. (E) After transfected with Mcl-1 siRNA or control siRNA for 24 h, the HCC cells were treated with 5 μM ABT-263 or vehicle DMSO for another 36 h. Then the cell viability was analyzed by CCK-8 kit. Data were expressed as the mean ± SD from three independent experiments. (*: P < 0.05; ***: P < 0.0001).

Back to article page